# PTC Therapeutics share price today (PTC Therapeutics, Inc., PTCT)

> PTC Therapeutics, Inc.'s balance sheet is under water: its net worth is negative, so it owes more than it owns. This is a high-risk situation: shareholders can be wiped out by new shares or a restructuring before the business recovers. PTCT · Healthcare · Biotechnology · data as of 5 November 2026. Page: https://www.sectoralpha.in/us/stocks/ptct

Sector Alpha also publishes a daily newsletter that explains one Indian stock at a time: https://newsletter.sectoralpha.in/?utm_source=sectoralpha&utm_medium=ai_text&utm_campaign=llms

## Key numbers

- Price: $65.67 (−8.5% in a year)
- P/E: 8.8× (higher than 57% of the last 1 year)
- Revenue (Jun 2026): $361 M (+101.5% on a year ago)
- Profit (Jun 2026): $83.5 M
- Operating margin: 41.3% (+60.8 points on a year ago)
- ROE: −333%, FY25

Biggest thing to watch: margins are the best this company has ever reported. Every ratio looks better at a record, so the story depends on margins staying high. ## What is the PTC Therapeutics share price today? PTC Therapeutics, Inc.'s share price was $65.67 at the close on 5 November 2026. It has been moving sideways for 13 weeks. That is 6.9% below its average price over the last 200 trading days. In the last 52 weeks it traded between $59 and $86, and at that close it sat 24% of the way up from that low. Over the past 13 weeks it has done worse than the S&P 500, and it has been behind for 14 weeks running. Over the last 10 years the share price moved +772% while the S&P 500 moved +245%, so it is ahead of the index over that whole period. It was last ahead over 13 weeks in the week of 31 July 2026. The chart above shows the 13-week comparison for every week. This page treats a rise as over when the price closes below its 200-day average on two Fridays in a row. ## What dividend does PTC Therapeutics pay? PTC Therapeutics, Inc. pays no dividend. In the last 12 reported quarters it declared no dividend per share, so there is no payout history to chart and no yield to show. Companies like this usually keep their earnings in the business, so the cash-flow sections show where that cash goes. ## Which stock lists is PTC Therapeutics on? PTC Therapeutics is not in the Nasdaq 100, the S&P 500 or the Dow Jones 30, and is not on the US tech stocks list. ## Is PTC Therapeutics profitable? PTC Therapeutics, Inc. earned $83.5 M of net profit in the Jun 2026 quarter. Full-year FY25 profit was $683 M. That is 23.2% of the quarter's revenue. The same quarter a year earlier lost $64.8 M. 9 of the last 12 reported quarters were loss-making. ## How much revenue does PTC Therapeutics make, and is it growing? PTC Therapeutics, Inc. reported $361 M of revenue in the Jun 2026 quarter, +101.5% on the same quarter a year earlier. Over 4 years it has grown 33.9% a year on average. The last full year, FY25, came in at $1.7 B. The last four reported quarters add to $1.0 B. FY25 revenue was $1.7 B, +114.5% on the year before. Recent pace: the last four quarters grew +2.3% on average, against 33.9% a year over the longer run, so this year is growing slower than its own long-run rate. Is growth speeding up? Revenue over the last 12 months grew −42.8%, against +5.8% a year over the last 8 quarters (rolling over). ## How much of every $100 of sales does PTC Therapeutics keep? PTC Therapeutics, Inc.'s operating margin was 41.3% in the Jun 2026 quarter, 60.8 percentage points higher than the same quarter a year ago. Its latest full-year margin is the highest it has ever reported. Across 5 years it has been between −69.6% and 49.5%. The latest quarter is within that range. Across 5 years it has been between −69.6% and 49.5%, and FY25's 49.5% is the highest of them. Why the margin moved: operating margin changed +60.8 percentage points on the year while gross margin changed +36.6 points. So the gain came mostly from the gross margin, which means input costs and prices charged. When margins are at a record, every ratio built on profit looks better than usual, so watch whether they hold. ## Is PTC Therapeutics' profit turning into cash? PTC Therapeutics, Inc.'s cash-flow history is too short to judge how much of its profit turns into cash. In FY25 it brought in $711 M of operating cash against $683 M of profit. After $8.9 M of spending on assets, $702 M was left over as free cash. Cash-flow figures here are yearly, because quarterly cash statements are not published, so this section changes once a year. What to look at next: the main use of cash is spending on assets. The next section checks what that spending is building. ## Where does PTC Therapeutics' cash go? PTC Therapeutics, Inc. does not report the customer, stock and supplier day counts a cash cycle needs, so this section looks at its spending on assets instead. It spent $43.8 M on assets over the last 3 years. Averaged over those years that is 0.8% of FY25 revenue a year. Nothing is estimated in place of the missing day counts, so no cash-cycle chart is drawn. Spending on assets: $43.8 M over the last 3 years. In short: the cash is going into new capacity, not getting stuck in the daily cycle. The question is whether the new capacity earns. ## What is PTC Therapeutics' P/E ratio, and how does it compare with its own history? PTC Therapeutics, Inc.'s P/E is 8.8×, in the middle of its own history: higher than 57% of past readings. Its usual P/E (the middle reading) is 8.6×, over 1 year of weekly prices. This compares the share price with the company’s own past. It does not say what the business is worth. In short: the multiple is about average against its own past, so the earnings trend underneath matters more than the multiple. ## Is the PTC Therapeutics business getting better or worse? PTC Therapeutics, Inc.'s business trend cannot be read yet. There are fewer than eight usable quarters of growth figures, so there is not enough history to read the trend. This is based on 12 quarters of 1 measure, with some gaps. Why it matters: with too little history, we say so rather than guess a direction. The return-on-capital line is not shown: net worth is negative, so a return on capital means nothing. The balance sheet is in distress, and this reading uses the growth lines alone. There are fewer than eight usable quarters, so this page does not guess a direction from so little history. ## How much does PTC Therapeutics earn on its capital? PTC Therapeutics, Inc. earned a ROE of −333% in FY25. That is up from a low of −36,433% in FY21. Its return on capital used (ROIC) is 3.6 percentage points above its cost of capital, so growth here adds value, not just size. It comes from a 39.4% net margin and 0.60× asset turnover (sales divided by assets). Why the return is what it is (FY25): a 39.4% net margin × 0.60× asset turnover × −14.12× leverage (assets divided by equity) ≈ −333.8% on equity. The margin does most of the work; borrowing plays a small part, so this return is earned, not borrowed. The key test, return on capital used minus the cost of capital: 10.1% − 6.5% = +3.6 percentage points. The 6.5% is an estimate of this company's own cost of capital. Read the sign and size of the gap, not the decimals. Positive but thin: it creates value with little room for error. The 10.1% ROIC above is the latest reading, as reported. The yearly chart below shows FY25 at 55.0%, and the quarterly chart works out each 12-month window from the quarterly figures, so the readings differ by date, not by method. ## Does PTC Therapeutics have too much debt? PTC Therapeutics, Inc.'s net worth is negative: it owes more than it owns, so a debt-to-equity ratio means nothing here. Year by year, that ratio went from 882.73 in FY21 to −13.19 in FY25. So the returns on this page come from the business, not from borrowed money. ## What is the PTC Therapeutics shareholding pattern? 11.3% of PTC Therapeutics, Inc.'s tradable shares are in short positions, which are bets that the price will fall, so a large group of traders is betting against it. At normal trading volumes, closing those positions would take about 6.4 days. US companies do not publish a quarter-by-quarter list of owners, so this page uses short interest instead. It is a single reading at one point in time; we do not have its history. Why it is at this level: the figure does not say who holds the short positions or why, so we show the level without guessing the story. ## How far is PTC Therapeutics from balance-sheet trouble? For PTC Therapeutics, Inc., the Z-score is 1.04. A Z-score above about 3 is safe and below about 1.8 signals danger, so this is in the danger zone. It estimates how far the balance sheet is from trouble; it is not a forecast of failure. Why it matters: a Z-score of 1.04 is inside the danger zone, so the balance sheet is a real risk. ## How does PTC Therapeutics rank in its industry? There is no score against its industry: PTC Therapeutics, Inc. is not among the largest members shown in this industry comparison for Biotechnology. The score ranks a company within its industry: each measure is scored against the other members. Without that group there is no score, so none is shown. ## Which companies is PTC Therapeutics compared with? No sector comparison is shown here, not among the largest members shown in this industry comparison. ## Which companies are close to PTC Therapeutics in size? PTC Therapeutics is the 43rd largest of 211 Biotechnology companies on Sector Alpha by market value (scores of 5 November 2026). Just above it: Ligand Pharmaceuticals Incorporated, CG Oncology, Inc. and Scholar Rock Holding Corporation. Just below it: CRISPR Therapeutics AG, Travere Therapeutics, Inc. and Dianthus Therapeutics, Inc. ### Biotechnology companies close in size

1. [Ligand Pharmaceuticals Incorporated](https://www.sectoralpha.in/us/stocks/lgnd) $6 billion
2. [CG Oncology, Inc.](https://www.sectoralpha.in/us/stocks/cgon) $5.7 billion
3. [Scholar Rock Holding Corporation](https://www.sectoralpha.in/us/stocks/srrk) $5.5 billion
4. PTC Therapeutics, Inc. $5.5 billion
5. [CRISPR Therapeutics AG](https://www.sectoralpha.in/us/stocks/crsp) $4.7 billion
6. [Travere Therapeutics, Inc.](https://www.sectoralpha.in/us/stocks/tvtx) $4.7 billion
7. [Dianthus Therapeutics, Inc.](https://www.sectoralpha.in/us/stocks/dnth) $4.6 billion

[All 211 Biotechnology companies, largest first](https://www.sectoralpha.in/us/sectors/biotechnology#all-companies)

### Companies close in size in other industries

1. [The Middleby Corporation](https://www.sectoralpha.in/us/stocks/midd) $5.8 billion · Specialty Industrial Machinery
2. [Riot Platforms, Inc.](https://www.sectoralpha.in/us/stocks/riot) $5.8 billion · Capital Markets
3. PTC Therapeutics, Inc. $5.8 billion
4. [The Cheesecake Factory Incorporated](https://www.sectoralpha.in/us/stocks/cake) $5.8 billion · Restaurants
5. [Trex Company, Inc.](https://www.sectoralpha.in/us/stocks/trex) $5.8 billion · Building Products & Equipment

## What else do people ask about PTC Therapeutics? ### What were PTC Therapeutics's latest quarterly results? PTC Therapeutics, Inc. reported revenue of $361 M and net profit of $83.5 M for the Jun 2026 quarter. Earnings per share were $0.92. The operating margin was 41.3%, 60.8 percentage points higher than a year earlier (as of 5 November 2026). ### What is PTC Therapeutics's market cap? PTC Therapeutics, Inc.'s market capitalisation is $5.5 B at a stock price of $65.67. Market cap is the share price times the number of shares, so it changes whenever the price moves (as of 5 November 2026). ### How is PTC Therapeutics performing? PTC Therapeutics, Inc.'s share price has been moving sideways for 13 weeks. Over the past 13 weeks it has done worse than the S&P 500, for 14 weeks running. This describes what the data did, not a rating (as of 5 November 2026). ### Will PTC Therapeutics's stock price go up? This page does not forecast PTC Therapeutics, Inc.'s stock price. What it shows instead: the stock price is $65.67, and it has been moving sideways for 13 weeks. Its P/E of 8.8× is higher than 57% of its own last 1 years (as of 5 November 2026). ### Where is PTC Therapeutics in its business cycle? PTC Therapeutics, Inc.'s FY25 operating margin was 49.5%, against a 5-year range of −69.6% to 49.5%: the top of its range, a record year. When profit is at a record, every ratio looks better than usual, and the story depends on margins staying high. The latest quarter was 41.3%. Comparing margins with a company's own long history is a good way to see where it is in its cycle (as of 5 November 2026). ### What could break the PTC Therapeutics story? Biggest thing to watch: margins are the best this company has ever reported. Every ratio looks better at a record, so the story depends on margins staying high. On price, this page treats a rise as over when the share price closes below its 200-day average on two Fridays in a row (as of 5 November 2026). ### Is PTC Therapeutics a stock worth studying right now? What the numbers show: PTC Therapeutics, Inc.'s balance sheet is under water: its net worth is negative, so it owes more than it owns. This is a high-risk situation: shareholders can be wiped out by new shares or a restructuring before the business recovers. The main open question: whether the business can earn its way back to positive net worth before new shares or a restructuring get there first. Every number on this page is worked out by code from the published figures, with no forecasts and no price opinions (as of 5 November 2026). This is research, not advice. We’re not SEBI-registered.